Paradigm Shift: From Contraindication to Controlled Indication
The evidence base has changed fundamentally over the past 15 years. Systematic reviews and prospective studies consistently show:
Comparable Survival Rates
HIV-positive patients under ART with CD4 > 200/μl and undetectable viral load show 5-year implant survival rates of 94–98% — comparable to the general population (95–98%). The difference is not statistically significant.
ART as the Key Factor
Antiretroviral therapy is the decisive factor. Patients under effective ART have largely normal immune function. Without ART or with treatment failure, complication risk increases significantly — not due to HIV itself, but due to the resulting immunosuppression.
Periodontal Prerequisites
HIV-positive patients have an increased risk for HIV-associated periodontitis (linear gingival erythema, necrotising periodontitis). The periodontal environment must be rehabilitated and stable before implantation — this is particularly critical in HIV patients.
ART Drug Interactions
Some ART regimens (particularly protease inhibitors) affect bone metabolism and can cause osteopenia/osteoporosis. Tenofovir (TDF) is associated with reduced bone density. These effects must be considered in preoperative diagnostics.
Current guideline position: The European Association for Osseointegration (EAO) and the American Academy of Periodontology (AAP) classify HIV under ART as a relative, not absolute contraindication. The decision is individual and depends on CD4 count, viral load, ART regimen and periodontal status.
CD4 Thresholds and Viral Load: The Decisive Parameters
| Immunological Status | Risk | Clinical Recommendation |
|---|---|---|
| CD4 > 500/μl + undetectable viral load | Very low | Implant possible; standard protocol with HIV specialist consultation |
| CD4 200–500/μl + viral load < 200 copies/ml | Low–Moderate | Implant possible; close follow-up; consider infection prophylaxis |
| CD4 200–500/μl + viral load > 200 copies/ml | Moderate | Therapy optimisation before implantation; HIV specialist consultation mandatory |
| CD4 < 200/μl (AIDS-defining threshold) | High | Implantation contraindicated until CD4 rises under ART; stabilise periodontal status |
| Acute opportunistic infection | Very high | Absolute contraindication; only after complete resolution and CD4 recovery |
| Stable ART > 6 months, CD4 > 200/μl | Low | Most favourable starting situation; implant with structured protocol recommended |
ART Regimens and Bone Health: What Implantology Needs to Know
Not all ART regimens have the same effect on bone metabolism. The following drug classes are particularly relevant for implantology:
Tenofovir Disoproxil Fumarate (TDF)
TDF is associated with the strongest reduction in bone mineral density (BMD) among all ART substances — on average 2–6% BMD loss in the first 2 years. For patients on TDF, CBCT bone density measurement before implantation is mandatory. Tenofovir alafenamide (TAF) has significantly lower bone effects and is preferred when implantation is planned.
Protease Inhibitors (PI): Lopinavir, Darunavir
Protease inhibitors inhibit osteoblast differentiation and promote osteoclast activity. Long-term PI therapy is associated with increased osteoporosis risk. Before implantation: DXA scan or CBCT Hounsfield analysis; if necessary, discuss regimen change with HIV specialist.
Integrase Inhibitors (INSTI): Dolutegravir, Bictegravir
INSTI-based regimens are considered the most bone-friendly ART option. Dolutegravir and bictegravir show minimal bone effects. Patients on INSTI-based ART with stable viral suppression have the most favourable risk profile for implants.
NNRTIs: Efavirenz, Rilpivirine
Non-nucleoside reverse transcriptase inhibitors have moderate bone effects. Efavirenz is associated with slightly increased osteoporosis risk; rilpivirine is considered more bone-friendly. Individual bone density measurement recommended.
Oral HIV Manifestations: Mandatory Pre-implant Rehabilitation
| Manifestation | Relevance for Implantology | Rehabilitation Measure |
|---|---|---|
| Linear Gingival Erythema (LGE) | Increased peri-implantitis risk | Professional cleaning, CHX rinse, control before implantation |
| Necrotising Ulcerative Gingivitis/Periodontitis (NUG/NUP) | Absolute contraindication until healed | Antibiotic therapy, periodontal rehabilitation, 3 months stabilisation |
| Oral Candidiasis | Increased wound infection risk | Antifungal therapy until clear; check CD4 status |
| Oral Kaposi Sarcoma | Contraindication in affected area | Oncological treatment; implantation only after complete remission |
| Oral Hairy Leukoplakia | Marker for immunosuppression (CD4 < 200) | ART optimisation; implantation only after CD4 rise |
| HPV-associated Lesions | Increased recurrence risk | Surgical removal; document HPV status |
Digital Protocol at IIDZ Vienna for HIV Patients
Interdisciplinary Pre-consultation
Before any implantation: written consultation with the attending HIV specialist (infectiologist). Goal: current CD4 count, viral load (< 200 copies/ml targeted), ART regimen, duration of viral suppression, history of opportunistic infections, current medication list.
CBCT Bone Density Measurement
Digital volume tomography with Hounsfield unit analysis of the implant site. For patients on TDF or PI: special attention to cortical density and trabecular structure. Hounsfield values < 300 HU (Type IV bone) require modified implantation protocol.
Virtual 3D Implant Planning
Planning with coDiagnostiX or Simplant based on CBCT data. With reduced bone density: longer implants, wider diameters, bone augmentation if necessary. Virtual simulation of primary stability (ISQ prognosis).
Periodontal Rehabilitation and Waiting Period
Complete periodontal rehabilitation before implantation mandatory. For NUG/NUP: at least 3 months stabilisation phase. Control: bleeding index < 20%, no active pockets > 4 mm, no oral HIV manifestations.
Guided Surgery with CAD/CAM Template
Individual drilling guide from CAD/CAM manufacturing transfers the virtual plan with millimetre precision. Minimises soft tissue trauma, reduces operating time and lowers infection risk through smaller wound surfaces — particularly relevant for immunocompromised patients.
Close Follow-up
HIV patients receive an intensified aftercare protocol: wound check after 3, 7 and 14 days; osseointegration check after 6 and 12 weeks; quarterly peri-implantitis control in the first year; annual ISQ measurement. If CD4 drops or viral load rises: immediate consultation with HIV specialist.
Current Evidence: Implant Survival Rates in HIV
| Patient Group | 1-Year Survival | 5-Year Survival | Note |
|---|---|---|---|
| HIV+ under ART, CD4 > 500/μl | 98–99% | 95–97% | Comparable to HIV-negative patients |
| HIV+ under ART, CD4 200–500/μl | 96–98% | 92–95% | Slightly increased peri-implantitis rate |
| HIV+ under ART, CD4 < 200/μl | 88–92% | 80–87% | Only after ART optimisation and CD4 rise |
| HIV-negative (reference) | 98–99% | 95–98% | General population |
Sources: Systematic reviews (Journal of Oral Implantology, Clinical Oral Implants Research, JOMI, 2018–2024). Survival rates vary by study, CD4 status and aftercare protocol.
Conclusion: HIV under ART is No Longer a Contraindication
HIV-positive patients under effective antiretroviral therapy can receive dental implants — with survival rates comparable to the general population. Decisive factors are CD4 count above 200/μl, undetectable viral load, stable ART regimen and rehabilitated periodontal environment. The ART regimen influences bone metabolism: TDF and protease inhibitors require special attention, INSTI-based regimens are more bone-friendly. IIDZ Vienna treats HIV patients according to a structured, interdisciplinary protocol — with CBCT diagnostics, virtual planning and close follow-up.
Corticosteroids and immunosuppressants as co-factors
Many HIV patients after transplantation take corticosteroids. Read how these affect implant healing: Dental Implant with Corticosteroids and Immunosuppressants
Kidney disease as a co-factor
HIV-associated nephropathy (HIVAN) can impair kidney function. Read our guide: Dental Implant with Kidney Disease and Dialysis
Aftercare after implantation
IIDZ Wien – Wissenschaftliche Redaktion
Wissenschaftliche Redaktion
Weitere Artikel
Thematisch verwandt
Hinweis: Diese Inhalte dienen ausschließlich der allgemeinen Information und ersetzen keine individuelle zahnärztliche Beratung. Das Institut für Implantologie und digitale Zahnmedizin Wien ist eine gemeinnützige, unabhängige Wissenschaftsplattform — kein Behandlungsbetrieb. Alle Angaben entsprechen dem aktuellen Stand der wissenschaftlichen Literatur; individuelle Behandlungsentscheidungen müssen stets mit einem approbierten Zahnarzt oder Facharzt getroffen werden.